All posts by: Michael Zand

About Michael Zand

Sangamo And Pfizer Announce First Patient Receives Treatment In Phase 1/2 Clinical Trial Evaluating SB-525 … – Markets Insider

Continue reading

2017-08-25 NEWS

Sangamo And Pfizer Announce First Patient Receives Treatment In Phase 1/2 Clinical Trial Evaluating SB-525 …
Markets Insider
25, 2017 /PRNewswire/ — Sangamo Therapeutics, Inc. (Nasdaq: SGMO) and Pfizer Inc. (NYSE: PFE) today announced that the first patient received treatment in the Phase 1/2 clinical trial (“the Alta trial”) evaluating SB-525, an investigational gene

and more »

Continue reading

2017-08-25 NEWS

Endpoints News

Regenxbio bags one of its gene therapy vector partners, buying out a struggling Dimension
Endpoints News
Gene therapy player Regenxbio $RGNX has struck a deal to buy the struggling Dimension Therapeutics $DMTX after a setback in the clinic earlier this year brutally hammered the biotech’s market cap down to only $30 million. Regenxbio has agreed to buy …
REGENXBIO to Acquire Dimension TherapeuticsNasdaq

all 5 news articles »

Continue reading

2017-08-25 NEWS

East Anglian Daily Times

Ed Sheeran’s backing sees thousands join stem cell register to help find seven-year-old Bury St Edmunds girl a donor
East Anglian Daily Times
Undated handout photo of Luke Concannon encouraging people to sign up to register as stem cell donors. Seven-year-old Jasmi Lindberg Cooke, who has been battling acute lymphoblastic leukaemia for three years, is desperately searching for a matching …

Continue reading

2017-08-25 NEWS

PMLiVE

NICE backs Europe’s first stem cell therapy
PMLiVE
Chiesi made history two years ago when it claimed the first approval in Europe for a stem cell therapy, and can now celebrate decision by NICE to recommend its product for routine use in England and Wales. The therapy – called Holoclar – was approved